Prior Authorization Web Form

Biologic Immunomodulators Initial

Biologic Immunomodulators Renewal

CGRP Inhibitors (Aimovig, Emgality, Ajovy) Initial

CGRP Inhibitors (Aimovig, Emgality, Ajovy) Renewal

Constipation Agents (Amitiza, Linzess, Trulance)

Diabetic Glucagon-like peptide agonists (GLP-1) (Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza). This is a closed formulary. Do not submit requests for NON-FORMULARY Adlyxin, Bydureon or Byetta. Non-formulary drugs are not subject to prior authorization review. Please submit questions to info@pcarx.com or fax to 210-624-8896.

Opioids (Extended Release)

Opioids (Immediate Release)

Stimulants [Provigil (modafinil), Nuvigil (armodafinil)]

Topical products for atopic dermatitis [Protopic (tacrolimus), Elidel (pimecrolimus), Eucrisa]

Weight Loss Agents (generic stimulants, Qysmia, Saxenda, Wegovy). This is a closed formulary. Do not submit requests for NON-FORMULARY Contrave or Xenical. Non-formulary drugs are not subject to prior authorization review. Please submit questions to info@pcarx.com or fax to 210-624-8896.

Other - Not Listed

Check if Urgent Note: The prescriber attests that applying the standard turnaround time could seriously jeopardize the life, health, or safety of the member or others, due to the member’s psychological state, or in the opinion of a practitioner with knowledge of the member’s medical or behavioral condition, would subject the member to adverse health consequences without the care or treatment that is the subject of the request.

Request Type

Request

Appeal

First Name

Last Name

Middle Name (optional)

Phone Number (optional)

Address (optional)

City

State

ZIP Code (optional) Format: 5 digits

Date of Birth Format: mm/dd/yyyy

Gender

Height (optional)

Weight (optional)

Allergies (optional)

Appointed Rep. (AOR) (optional)

AOR Phone Number (optional)

Insurance Information

Primary Insurance Name

Primary Insurance ID Number

Secondary Insurance Name (optional)

Secondary Insurance ID Number (optional)

Prescriber Information

NPI Number (individual)

First Name

Last Name

Specialty

Address

City

State

ZIP Code

Phone Number

Fax Number (in HIPAA-compliant area)

Email Address (optional)

DEA Number (if required)

Office Contact Person (optional)

Requestor (if not the prescriber)

Medication/Medical and Dispensing Information

Medication to Search For Partial matches are allowed, starting with the beginning of the medication's name. (minimum of 3 characters required)

Quantity

Days Supply

Frequency

Total Number of Fills

Pharmacy Name (optional)

Pharmacy Phone Number (optional)

Pharmacy Fax Number (optional)

New Therapy

Renewal

Dispense As Written Note: If not checked, the request will be reviewed as "Generic Substitution Permitted"

Date Therapy Initiated (if renewal) Date format: mm/dd/yyyy

Duration of Therapy (specific dates)

Administration

Oral/SL

Topical

Injection

Other

Administration Location

Physician's Office

Ambulatory Infusion Center

Patient's Home

Home Care Agency

Outpatient Hospital Care

Long Term Care

Other

Has the patient tried any other medications for this condition?

Yes

If Yes, complete the three fields below.

Medication/Therapy (Drug Name and Dosage)

Duration of Therapy (Specify Dates)

Reason for Failure/Response/Allergy

Diagnoses

List of Diagnoses

ICD-10 Codes (if available)

Clinical Information Please provide all relevant clinical information to support a prior authorization review.

Clinical Explanation

List of Current Medications

Additional documentation included in attachments

Additional Attachments PDF files only. Maximum of 50 pages per attachment. Larger documents should be faxed to (833) 676-2016.

I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, Insurer, Medical Group, or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Signature (enter name)

Signature Date Format: mm/dd/yyyy

Confidentiality Notice: The documents accompanying this submission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please arrange for the return or destruction of these documents immediately.